#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of Ripasudil Eye Drops for Patients with Fuchs Endothelial Corneal Dystrophy After Descemetorhexis

3 1

What is this study about?

This clinical trial is focused on studying Fuchs Endothelial Corneal Dystrophy, a condition affecting the cornea, which is the clear front part of the eye. The study is investigating the safety and effectiveness of Ripasudil (also known by its code name K-321) eye drops. These eye drops are being tested to see if they can help improve vision after a procedure called descemetorhexis, which involves removing a small part of the cornea to treat the disease.

The purpose of the study is to see how quickly vision improves after using the Ripasudil eye drops compared to a placebo, which is a substance with no active medication. Participants will be randomly assigned to receive either the Ripasudil eye drops or the placebo. The study will last for a total of 12 weeks, with an additional two-week period where the dose is gradually reduced, followed by a 38-week follow-up phase to monitor long-term effects.

Throughout the study, participants will have their vision checked regularly to see how well they can see letters on a chart, which is a common way to measure vision improvement. The study aims to determine if the eye drops can help achieve a significant improvement in vision during the first 12 weeks after the procedure. Participants will also be monitored for any changes in the cornea and any side effects from the treatment.

1 initial treatment phase

The study begins with the administration of ripasudil eye drops. These are used to treat Fuchs Endothelial Corneal Dystrophy, a condition affecting the cornea of the eye.

The eye drops are applied directly to the eye, a method known as ocular use.

2 treatment duration

The treatment with ripasudil eye drops lasts for a period of 12 weeks. During this time, the effect on vision improvement is closely monitored.

The goal is to achieve an improvement in visual acuity, measured by the ability to read letters on an eye chart.

3 dose taper phase

After the initial 12-week treatment period, there is a two-week phase where the dosage of the eye drops is gradually reduced. This is known as the dose taper phase.

4 follow-up phase

Following the dose taper phase, there is a 38-week follow-up period. During this time, the long-term effects of the treatment are assessed.

The follow-up phase helps to determine the overall safety and effectiveness of the treatment.

Who Can Join the Study?

  • The person must be at least 18 years old.
  • The person must have a diagnosis of Fuchs Endothelial Corneal Dystrophy (FECD), which is a condition affecting the cornea of the eye.
  • The person must have a specific pattern in the cornea called confluent central guttae that can be removed by a procedure called descemetorhexis, which involves removing a small circular area of the cornea.
  • The person must have one of the following vision issues in the study eye:
    • Vision measured at 78 letters or fewer on a specific eye test called ETDRS, which is similar to a Snellen chart reading of 20/32 or worse.
    • Vision measured at more than 78 letters on the ETDRS test but experiencing problems like glare, stray light, or difficulty seeing contrasts.
  • The person must be able to understand and sign a written consent form, agreeing to follow the study’s rules and procedures.
  • After the descemetorhexis procedure, it must be confirmed that the central area of the cornea with confluent guttae has been removed, measuring between 4.5 to 5.5 mm in diameter.

Who Cannot Join the Study?

  • Patients who do not have Fuchs Endothelial Corneal Dystrophy cannot participate. This is a condition affecting the clear front part of the eye called the cornea.
  • Patients who are not within the specified age range cannot participate. The age range is typically defined by the study.
  • Patients who are not part of the specified clinical trial groups cannot participate. These groups are usually defined by the study based on certain characteristics.
  • Patients who are not male or female cannot participate, as the study includes both genders.
  • Patients who are considered part of a vulnerable population cannot participate. This refers to groups who may need special protection in research, such as children or those with certain disabilities.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Universitaetsklinikum Heidelberg AöR Heidelberg Germany
Universitaet Leipzig Leipzig Germany

Other Sites

Site Name City Country Status
Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada Manresa Spain
Instituto Oftalmologico Fernandez-Vega S.L. Oviedo Spain
Institut Catala De Retina S.L. Barcelona Spain
Universitaetsklinikum Erlangen AöR Erlangen Germany
Universitaetsklinikum Tuebingen AöR Tuebingen Germany
Saarland University Hospital Homburg Germany
Rigshospitalet Copenhagen Denmark
Metavision Arruzafa S.L. Cordoba Spain
Oilogxmaxmdn Vlctihqpjajg She Barcelona Spain
Urwayueagg Hzinrnbc Cwlydbc Cologne Germany
Ubuiahsnhywyitkbhszcx Dbeovirhoml Auj Duesseldorf Germany
Adonqx Ulftdjgyqr Hydztmvz Aarhus Denmark
Khhhfmlf dqv Uvpczxwnbhph Myzpjgue Amv Munich Germany
Hirirqep Uopkrqiyzfdia Hwtqgwqj Tfsmj y Pydifd Iimqugro Civwhr djcukrzcueolgvhsa (hpsn Badalona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Denmark Denmark
Not recruiting
04.04.2023
Germany Germany
Not recruiting
04.04.2023
Spain Spain
Not recruiting
04.04.2023

Trial locations

Investigated drugs:

Ripasudil (K-321) Eye Drops are being studied to see if they can help improve vision in people with Fuchs Endothelial Corneal Dystrophy. This condition affects the cornea, the clear front part of the eye, and can lead to vision problems. The eye drops are used after a procedure called descemetorhexis, which involves removing a layer of cells from the cornea. The study aims to find out if these eye drops can help improve vision by increasing the number of letters a person can read on an eye chart.

Investigated diseases:

Fuchs Endothelial Corneal Dystrophy – This is an eye condition that affects the cornea, the clear front surface of the eye. It is characterized by the gradual deterioration of the endothelial cells, which are responsible for maintaining the cornea’s clarity by pumping out excess fluid. As these cells are lost, fluid builds up in the cornea, leading to swelling and clouding of vision. Over time, this can cause blurred vision, glare, and discomfort, especially in the morning. The disease typically progresses slowly and may initially affect one eye before the other. It is more common in older adults and can lead to significant visual impairment if not managed.

Trial ID:
2024-511752-40-00
Protocol code:
K-321-301
NCT ID:
NCT05795699
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on Nepafenac and Dexamethasone for Reducing Inflammation and Swelling in Fuchs Dystrophy Patients After Corneal Transplant

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on the Effectiveness and Safety of STN1010904 Eye Drops for Patients with Fuchs Endothelial Corneal Dystrophy

    Not recruiting

    2 1
    Investigated drugs:
    France